News

New teaching tool could help doctors screen for PsA


 

References

A new teaching tool based on the acronym mnemonic PSA may help doctors to screen for psoriatic arthritis in patients with psoriasis or a strong family history of it.

The tool tells physicians to ask patients whether they are experiencing core features of psoriatic arthritis (PsA). Such features are tied to the acronym PSA. P stands for pain in the joints, S stands for stiffness more than 30 minutes after a period of inactivity and for sausage digits, and A represents axial spine involvement or back pain associated with stiffness that improves with activity. If patients with psoriasis and/or a strong family history of psoriasis say they are experiencing at least two of those features, then they “would have a higher than average chance of a PsA diagnosis,” according to Jeffrey M. Cohen and his colleagues.

Benefits of the tool include its ease of use and short administration time; it also covers “the core domains” of the disease, just like many of the current PsA screening tools.

The tool is limited, however, because it is unlikely to be as specific as the longer PsA screening instruments and it calls for questioning patients about features of PsA that are also features of other pathologies. Additionally, the tool is more specific to diagnosing seronegative peripheral and axial spondyloarthritides than inflammatory arthritis. It also is useful for distinguishing between noninflammatory arthritis and inflammatory arthritis.

“We feel this teaching tool, while not specific for PsA, will help the nonrheumatologist begin to differentiate inflammatory from noninflammatory musculoskeletal pain and therefore prompt an appropriate referral for work-up,” the researchers wrote.

Read the full paper in the Journal of the American Academy of Dermatology (doi:10.1016/j.jaad.2014.12.008).

Recommended Reading

Methotrexate and biologics linked to higher zoster risk in psoriasis
MDedge Internal Medicine
No increased risk of lung disease with methotrexate
MDedge Internal Medicine
Traditional risk factors raise cardiovascular risk in PsA
MDedge Internal Medicine
Ixekizumab met psoriasis endpoints by week 12, with durable response at 60 weeks
MDedge Internal Medicine
Apremilast meets psoriasis endpoints at week 32
MDedge Internal Medicine
Psoriatic arthritis associated with heavy drinking
MDedge Internal Medicine
New psoriatic arthritis screening tool passes initial validation
MDedge Internal Medicine
Contamination prompts voluntary injectables recall
MDedge Internal Medicine
Late-onset psoriasis genetics identified
MDedge Internal Medicine
Older psoriasis patients experience more adverse events
MDedge Internal Medicine